|
Orthologous residues
|
|
DARPP‑32 (human): T75‑p, DARPP‑32 (mouse): T75‑p, DARPP‑32 (rat): T75‑p, DARPP‑32 (cow): T75‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'brain, striatum'
|
|
Cellular systems studied:
tissue
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
PHOSPHATASE
|
PPP2CA (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
caffeine
|
|
|
|
increase
|
|
|
roscovitine
|
caffeine
|
|
|
inhibit treatment-induced increase
|
|
|
SCH 58261
|
|
|
|
increase
|
|
|
CGS 21680
|
|
|
|
decrease
|
|
|
okadaic acid
|
CGS 21680
|
|
|
inhibit treatment-induced decrease
|
|
|
okadaic acid
|
|
|
|
increase
|
|
|
